search
Back to results

Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine

Primary Purpose

Lower Back Pain

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Elaspine™
Sponsored by
Spinelab AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lower Back Pain focused on measuring Back Pain,, Back Pains, Low, Low Back Pains, Pain, Low Back, Pains, Low Back, Lumbago, Lower Back Pain, Back Pain, Lower, Back Pains, Lower, Lower Back Pains, Pain, Lower Back, Pains, Lower Back, Low Back Ache, Ache, Low Back, Aches, Low Back, Back Ache, Low, Back Aches, Low, Low Back Aches, Low Backache, Backache, Low, Backaches, Low, Low Backaches, Low Back Pain, Recurrent, Recurrent Low Back Pain, Low Back Pain, Postural, Postural Low Back Pain, Low Back Pain, Mechanical, Mechanical Low Back Pain, Low Back Pain, Posterior Compartment

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient has signed and understood the approved Informed Consent form and is able to meet the proposed follow-up and postoperative management program.
  2. Patient is skeletally mature and between 21 - 80 years of age.
  3. Patient's pre-operative Body Mass Index (BMI) is ≤ 34.
  4. Patient's pre-operative Oswestry Disability Index (ODI) is ≥ 30% (≥15 out of 50 points).
  5. Patient's pre-operative back pain Visual Analogue Scale (VAS) is >60 (0-100 scale), with or without associated leg pain (leg pain VAS score).
  6. Patient has received non-operative treatment for low back pain for > 6 months and is unresponsive.
  7. Patient has one or more of the following structural abnormalities with imaging studies verifying them at one or two contiguous levels within L1-L5:

    • Discopathy
    • Degenerative disc disease
    • Massive or recurrent disc herniation
    • Non-isthmic spondylolisthesis ≤ Grade 1 (acc. To Meyerding)
    • Spinal stenosis
    • Partially defective facet joints
    • Retrolisthesis according to one of the following definitions (acc. to Ruch, William J.; Literature Reference 21):

      • Complete Retrolisthesis: The body of one vertebra is posterior to both the vertebral body of the segment of the spine above as well as below
      • Stairstepped Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment above, but is anterior to the one below.
      • Partial Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment either above or below.

Exclusion Criteria:

  1. Degenerative spondylolisthesis greater than Grade 1 as defined by greater than 25 percent vertebral slip forward over the inferior vertebral body (acc. to Meyerding Classification) or significant segmental instability at or adjacent to intended treatment level.
  2. Need for more than two-level or two non-contiguous-level surgery in the lumbar spine.
  3. Patient has more than 50% defective facet joint (half of the articular joint surface) or laminectomy
  4. Patient is scheduled for another lumbar surgery such as but not limited to a fusion
  5. Patient has recent vertebral fractures or past fractures which did not heal.
  6. Patient has known allergies to titanium alloy and polycarbonate urethane (PCU).
  7. Patient has clinically compromised vertebral body structure and morphology at the lumbar spine due to current or past trauma (or pathological vertebral fracture) or significant endplate incompetence such as Schmorl´s node.
  8. Patient has spondylolysis at the levels to be treated or an adjacent level.
  9. Patient has a frontal curve in the lumbar spine >10°.
  10. Patient has previously been diagnosed osteopenia or metabolic bone diseases or severe osteoporosis - if suspected to be confirmed by bone density being 2.5 SD below normal as assessed using DEXA analysis in:

    • Postmenopausal females if suggested by x-ray or other risk factors
    • Males over the age of 60 that have sustained a non-traumatic hip or spine fracture
  11. Patient is taking medications known to potentially interfere with bone/soft tissue healing, including but not limited to the long term use of corticosteroids. (This is not intended to exclude patients using inhalation medications for asthma.)
  12. Patient has an active infection either systemic or at the local site of intended surgery.
  13. Patient has been diagnosed with hepatitis, rheumatoid arthritis, an autoimmune disease, or AIDS, ARC, or is HIV positive or any other diseases that according to surgeons may have an impact on the outcome of the surgery.
  14. Patients with known malignant diseases or bone tumors.
  15. Patients with vascular malformations such as abdominal aneurysm.
  16. Patient has a progressive neuromuscular disease. Patient has active malignancy within the last 15 years, unless the malignancy was treated with curative intent and there have been no clinical signs or symptoms for at least 5 years.
  17. Patient has cervical myelopathy.
  18. Patient is pregnant or planning in becoming pregnant in the next 2 years.
  19. Patient is currently participating in another investigational study where the endpoints have not yet been achieved. 8/35 Elaspine™ PMCS 01, Clinical Investigation Plan CIP EN Version C, October 1st, 2010 CONFIDENTIAL
  20. Patient has mental illness, and/or diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise ability to provide informed consent or compliance with follow-up requirements. If suspected to be confirmed by classification according to DSM IV.
  21. Patient has had another surgical procedure(s) within the last 60 days involving general anesthesia or any surgical procedure that might increase the risk of deep vein thrombosis.
  22. Loss of Disk height according to Pfirrmann (> C) or Frymoyer (>3) and or severe spondylosis.
  23. Patient shows three or more signs of anorganic behaviour (Waddell´s signs).

Sites / Locations

  • Helios Rosmann Klinik
  • Stauferklinikum Schwäbisch Gmünd
  • HSK Dr. Horst-Schmidt-Klinik
  • Katholisches Klinikum Marienhof
  • HUG Hôpitaux Universitaires de Genève

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Elaspine™

Arm Description

Impantation of Elaspine™ device

Outcomes

Primary Outcome Measures

Safety
Incidence (including severity) of operative and post-operative complications throughout the first 3 months postoperatively by category (general, operative, post-operative, possibly device related etc.)
Performance
Defined as the incidence of device complications and device malfunctions (including severity), as assessed by radiographic evaluation throughout the first 12 months post-operatively. Device malfunctions include, but are not limited to loosening or breakage of the pedicle screws, disassembly of the locking clip, breakage of the rod, pathological motion or stiffness of the segments and disc collapse. Reading of the imaging studies will be centralized at an independent facility.

Secondary Outcome Measures

Changes in function status (ODI), back pain (VAS) and health status (SF-12) at two-years post-operatively will be measured and compared to the preoperative baseline
Changes in neurologic function at two-years post-operatively as compared to the preoperative baseline by motor, sensory, reflexes and straight leg raise
Changes in angular range of motion from maximum flexion to extension between preoperative baseline and the two-year postoperative outcome assessed by radiographic imaging (dynamic xrays)

Full Information

First Posted
March 24, 2011
Last Updated
November 16, 2015
Sponsor
Spinelab AG
Collaborators
UL International GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT01323543
Brief Title
Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine
Official Title
"Elaspine™ Implant System Post Marketing Clinical Study: A Prospective, Multicentre Study to Evaluate the Safety and Performance of the Elaspine™ System in the Surgical Treatment of Degenerative Lumbar Spine"
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spinelab AG
Collaborators
UL International GmbH

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The safety and performance of the Elaspine™ Implant System in the treatment of lower back pain will be evaluated with a prospective and nonrandomized, multicenter post-marketing clinical study (PMCS). The study will be enrolled within Germany and Switzerland in 3-5 clinical centres, including in average 10 patients per centre. The study is conducted in accordance with the Standard ISO 14155, where applicable on clinical investigation of medical devices for human subjects and other legal requirements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lower Back Pain
Keywords
Back Pain,, Back Pains, Low, Low Back Pains, Pain, Low Back, Pains, Low Back, Lumbago, Lower Back Pain, Back Pain, Lower, Back Pains, Lower, Lower Back Pains, Pain, Lower Back, Pains, Lower Back, Low Back Ache, Ache, Low Back, Aches, Low Back, Back Ache, Low, Back Aches, Low, Low Back Aches, Low Backache, Backache, Low, Backaches, Low, Low Backaches, Low Back Pain, Recurrent, Recurrent Low Back Pain, Low Back Pain, Postural, Postural Low Back Pain, Low Back Pain, Mechanical, Mechanical Low Back Pain, Low Back Pain, Posterior Compartment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Elaspine™
Arm Type
Experimental
Arm Description
Impantation of Elaspine™ device
Intervention Type
Device
Intervention Name(s)
Elaspine™
Intervention Description
Implantation of device
Primary Outcome Measure Information:
Title
Safety
Description
Incidence (including severity) of operative and post-operative complications throughout the first 3 months postoperatively by category (general, operative, post-operative, possibly device related etc.)
Time Frame
24 months
Title
Performance
Description
Defined as the incidence of device complications and device malfunctions (including severity), as assessed by radiographic evaluation throughout the first 12 months post-operatively. Device malfunctions include, but are not limited to loosening or breakage of the pedicle screws, disassembly of the locking clip, breakage of the rod, pathological motion or stiffness of the segments and disc collapse. Reading of the imaging studies will be centralized at an independent facility.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Changes in function status (ODI), back pain (VAS) and health status (SF-12) at two-years post-operatively will be measured and compared to the preoperative baseline
Time Frame
24 months
Title
Changes in neurologic function at two-years post-operatively as compared to the preoperative baseline by motor, sensory, reflexes and straight leg raise
Time Frame
24 months
Title
Changes in angular range of motion from maximum flexion to extension between preoperative baseline and the two-year postoperative outcome assessed by radiographic imaging (dynamic xrays)
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has signed and understood the approved Informed Consent form and is able to meet the proposed follow-up and postoperative management program. Patient is skeletally mature and between 21 - 80 years of age. Patient's pre-operative Body Mass Index (BMI) is ≤ 34. Patient's pre-operative Oswestry Disability Index (ODI) is ≥ 30% (≥15 out of 50 points). Patient's pre-operative back pain Visual Analogue Scale (VAS) is >60 (0-100 scale), with or without associated leg pain (leg pain VAS score). Patient has received non-operative treatment for low back pain for > 6 months and is unresponsive. Patient has one or more of the following structural abnormalities with imaging studies verifying them at one or two contiguous levels within L1-L5: Discopathy Degenerative disc disease Massive or recurrent disc herniation Non-isthmic spondylolisthesis ≤ Grade 1 (acc. To Meyerding) Spinal stenosis Partially defective facet joints Retrolisthesis according to one of the following definitions (acc. to Ruch, William J.; Literature Reference 21): Complete Retrolisthesis: The body of one vertebra is posterior to both the vertebral body of the segment of the spine above as well as below Stairstepped Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment above, but is anterior to the one below. Partial Retrolisthesis: The body of one vertebra is posterior to the body of the spinal segment either above or below. Exclusion Criteria: Degenerative spondylolisthesis greater than Grade 1 as defined by greater than 25 percent vertebral slip forward over the inferior vertebral body (acc. to Meyerding Classification) or significant segmental instability at or adjacent to intended treatment level. Need for more than two-level or two non-contiguous-level surgery in the lumbar spine. Patient has more than 50% defective facet joint (half of the articular joint surface) or laminectomy Patient is scheduled for another lumbar surgery such as but not limited to a fusion Patient has recent vertebral fractures or past fractures which did not heal. Patient has known allergies to titanium alloy and polycarbonate urethane (PCU). Patient has clinically compromised vertebral body structure and morphology at the lumbar spine due to current or past trauma (or pathological vertebral fracture) or significant endplate incompetence such as Schmorl´s node. Patient has spondylolysis at the levels to be treated or an adjacent level. Patient has a frontal curve in the lumbar spine >10°. Patient has previously been diagnosed osteopenia or metabolic bone diseases or severe osteoporosis - if suspected to be confirmed by bone density being 2.5 SD below normal as assessed using DEXA analysis in: Postmenopausal females if suggested by x-ray or other risk factors Males over the age of 60 that have sustained a non-traumatic hip or spine fracture Patient is taking medications known to potentially interfere with bone/soft tissue healing, including but not limited to the long term use of corticosteroids. (This is not intended to exclude patients using inhalation medications for asthma.) Patient has an active infection either systemic or at the local site of intended surgery. Patient has been diagnosed with hepatitis, rheumatoid arthritis, an autoimmune disease, or AIDS, ARC, or is HIV positive or any other diseases that according to surgeons may have an impact on the outcome of the surgery. Patients with known malignant diseases or bone tumors. Patients with vascular malformations such as abdominal aneurysm. Patient has a progressive neuromuscular disease. Patient has active malignancy within the last 15 years, unless the malignancy was treated with curative intent and there have been no clinical signs or symptoms for at least 5 years. Patient has cervical myelopathy. Patient is pregnant or planning in becoming pregnant in the next 2 years. Patient is currently participating in another investigational study where the endpoints have not yet been achieved. 8/35 Elaspine™ PMCS 01, Clinical Investigation Plan CIP EN Version C, October 1st, 2010 CONFIDENTIAL Patient has mental illness, and/or diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise ability to provide informed consent or compliance with follow-up requirements. If suspected to be confirmed by classification according to DSM IV. Patient has had another surgical procedure(s) within the last 60 days involving general anesthesia or any surgical procedure that might increase the risk of deep vein thrombosis. Loss of Disk height according to Pfirrmann (> C) or Frymoyer (>3) and or severe spondylosis. Patient shows three or more signs of anorganic behaviour (Waddell´s signs).
Facility Information:
Facility Name
Helios Rosmann Klinik
City
Breisach
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
79206
Country
Germany
Facility Name
Stauferklinikum Schwäbisch Gmünd
City
Mutlangen
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
73557
Country
Germany
Facility Name
HSK Dr. Horst-Schmidt-Klinik
City
Wiesbaden
State/Province
Hessia
ZIP/Postal Code
65199
Country
Germany
Facility Name
Katholisches Klinikum Marienhof
City
Koblenz
State/Province
Rhineland-Palatinate
ZIP/Postal Code
56073
Country
Germany
Facility Name
HUG Hôpitaux Universitaires de Genève
City
Geneva
ZIP/Postal Code
1211
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine

We'll reach out to this number within 24 hrs